Moxonidin Actavis (Moxonidine)

Moxonidine acts as a selective agonist at imidazoline I1 receptors in the brainstem. Activation of these receptors reduces sympathetic nervous system outflow, leading to decreased peripheral vascular resistance and heart rate, which together lower arterial blood pressure.

The dose of Moxonidin Actavis is individualized. A qualified prescriber determines the appropriate strength and dosing schedule based on the patient’s blood pressure, renal function, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Limited clinical data are available for moxonidine use in pregnancy and lactation. Because potential risks cannot be ruled out, it is generally not recommended unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare provider is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxonidine belongs to the central imidazoline agonist class, differing from ACE inhibitors, ARBs, calcium‑channel blockers and beta‑blockers that act peripherally. It offers a modest blood‑pressure reduction with a lower incidence of metabolic side effects, but may cause more central nervous system effects such as dry mouth or dizziness.

Moxonidin Actavis tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

The medication is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber to maintain consistent blood‑pressure control.

Serious adverse events, although uncommon, include severe hypotension, marked bradycardia, allergic reactions such as rash or angioedema, and significant liver‑enzyme elevations. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, or signs of an allergic reaction.

Moxonidin Actavis is contraindicated in patients with known hypersensitivity to moxonidine, severe hypotension, recent myocardial infarction, or those taking other central imidazoline agonists. Caution is also advised for individuals with severe renal impairment or certain cardiac conditions.